Adjuvant effect of antimicrobial photodynamic therapy on non-surgical periodontal treatment in patients with and without diabetes and on surgical periodontal treatment

• Grant number: 17/07208-7
• Support Opportunities: Regular Research Grants
• Start date: February 01, 2019
• End date: April 30, 2021
• Field of knowledge: Health Sciences - Dentistry - Periodontology
• Principal Investigator: Carla Andreotti Damante
• Grantee: Carla Andreotti Damante
• Host Institution: Faculdade de Odontologia de Bauru (FOB). Universidade de São Paulo (USP). Bauru , SP, Brazil

Abstract

Antimicrobial photodynamic therapy (aPDT) has been applied as adjuvant periodontal treatment. Positive results of aPDT association to scaling and root planing (SRP) are reported for healthy and systemically compromised patients. On the other side, rare information is available for this association to periodontal surgical therapy. The aim of this study is to evaluate the effects of aPDT associated to SRP in type 1 diabetes and healthy patients and in regenerative surgical treatment of class II furcation. In addition, quality of life of patients will be evaluated. In the first study 76 patients (38 healthy, 38 type 1 diabetes) will be treated by SRP or SRP associated to aPDT (Methilene blue 10mg/ml, red laser, 100mW, 8J/tooth, 4 sessions). At baseline, 3 and 6 months, clinical periodontal parameters (probing depth, clinical attachment level, bleeding on probing) and, salivary parameters (pH, buffer capacity, salivary glycemia) will be evaluated. Capillary glycemia will be measured in all patients and glycated hemoglobin only in diabetic patients. The second study consists on treating class II furcations (inferior molars - 15 patients) by SRP and regeneration with bovine bone and resorbable membrane or SRP associated to aPDT and the same regenerative treatment. The same clinical periodontal parameters plus will be analyzed at baseline, 3 and 6 months and radiographic osseous filling at baseline and 12 moths. In the first study gingival fluid will be collected for biomarkers quantification by Luminex multianalyte immunoassay (1st study: IL-1², IL-4, IL-6, IL-8, TNF-alfa). The third study will evaluate quality of life of patients receiving all treatments. Statistical analysis will be done by parametric and non-parametric tests depending on sample distribution and correlation tests. Level of significance will be 5% (P<0,05). (AU)